These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 11444651)
1. Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease. Hennekens CH Clin Cardiol; 2001; 24(7 Suppl):II-2-5. PubMed ID: 11444651 [TBL] [Abstract][Full Text] [Related]
2. Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom. Reynolds TM; Pottle A; Quoraishi SH Vasc Health Risk Manag; 2021; 17():227-237. PubMed ID: 34054297 [TBL] [Abstract][Full Text] [Related]
3. Total lipid management and residual risk: beyond statin therapy. Evans M Br J Hosp Med (Lond); 2011 Mar; 72(3):132-6. PubMed ID: 21475092 [TBL] [Abstract][Full Text] [Related]
4. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N BMJ; 2022 May; 377():e069066. PubMed ID: 35508320 [TBL] [Abstract][Full Text] [Related]
5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of lipid-lowering therapy beyond statins to prevent cardiovascular events: a meta-analysis. Dykun I; Mincu R; Hendricks S; Balcer B; Totzeck M; Rassaf T; Mahabadi AA Eur J Prev Cardiol; 2020 Oct; 27(15):1675-1678. PubMed ID: 31357886 [No Abstract] [Full Text] [Related]
7. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Tenenbaum A; Fisman EZ; Motro M; Adler Y Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960 [TBL] [Abstract][Full Text] [Related]
8. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766 [TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapies for lipid modification: beyond the statins. Gotto AM; Moon JE Nat Rev Cardiol; 2013 Oct; 10(10):560-70. PubMed ID: 23959229 [TBL] [Abstract][Full Text] [Related]
11. Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Jacobson TA Mayo Clin Proc; 2011 Aug; 86(8):762-80. PubMed ID: 21803958 [TBL] [Abstract][Full Text] [Related]
14. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP; JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716 [TBL] [Abstract][Full Text] [Related]
15. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib. Miyares MA; Davis K Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305 [TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs. Butters J; Brown A; Griffith L; Kim S; Nicholls SJ Am J Cardiovasc Drugs; 2017 Dec; 17(6):447-452. PubMed ID: 28432573 [TBL] [Abstract][Full Text] [Related]
17. Statins: a brief summary. Pfeffer MA Clin Cardiol; 2001; 24(7 Suppl):II-18. PubMed ID: 11444650 [TBL] [Abstract][Full Text] [Related]
18. Lipid-lowering drug use and cardiovascular events after myocardial infarction. Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147 [TBL] [Abstract][Full Text] [Related]
19. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124 [TBL] [Abstract][Full Text] [Related]
20. [Kidney and statins]. Moulin B; Caillard S Ann Endocrinol (Paris); 2001 Feb; 62(1 Pt 2):121-7. PubMed ID: 11240414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]